Atrogin-1 inhibits Akt-dependent cardiac hypertrophy in mice via ubiquitin-dependent coactivation of Forkhead proteins
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Cardiac hypertrophy is a major cause of human morbidity and mortality. Although much is known about the pathways that promote hypertrophic responses, mechanisms that antagonize these pathways have not been as clearly defined. Atrogin-1, also known as muscle atrophy F-box, is an F-box protein that inhibits pathologic cardiac hypertrophy by participating in a ubiquitin ligase complex that triggers degradation of calcineurin, a factor involved in promotion of pathologic hypertrophy. Here we demonstrated that atrogin-1 also disrupted Akt-dependent pathways responsible for physiologic cardiac hypertrophy. Our results indicate that atrogin-1 does not affect the activity of Akt itself, but serves as a coactivator for members of the Forkhead family of transcription factors that function downstream of Akt. This coactivator function of atrogin-1 was dependent on its ubiquitin ligase activity and the deposition of polyubiquitin chains on lysine 63 of Foxo1 and Foxo3a. Transgenic mice expressing atrogin-1 in the heart displayed increased Foxo1 ubiquitylation and upregulation of known Forkhead target genes concomitant with suppression of cardiac hypertrophy, while mice lacking atrogin-1 displayed the opposite physiologic phenotype. These experiments define a role for lysine 63-linked ubiquitin chains in transcriptional coactivation and demonstrate that atrogin-1 uses this mechanism to disrupt physiologic cardiac hypertrophic signaling through its effects on Forkhead transcription factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of ubiquitin ligases required for skeletal muscle atrophy.
Bodine, S. C., Latres, E., Baumhueter, S., Lai, V. K.-M., Nunez, L., Clarke, B. A., Poueymirou, W. T., Panaro, F. J., Na, E., Dharmarajan, K., et al. (2001) · Science · doi:10.1126/science.1065874 · Cited by 3,521
Self-citationSandri, M., Sandri, C., Gilbert, A., Skurk, C., Calabria, E., Picard, A., Walsh, K., Schiaffino, S., Lecker, S. H., & Goldberg, A. L. (2004) · Cell · doi:10.1016/s0092-8674(04)00400-3 · Cited by 3,012
Cited by
Regulation of skeletal muscle growth by the IGF1-Akt/PKB pathway: insights from genetic models
Schiaffino, S., & Mammucari, C. (2011) · Skeletal Muscle · doi:10.1186/2044-5040-1-4 · Cited by 816
“In another feed-forward mechanism, MAFbx, which is activated by FoxO, acts in turn as coactivator of FoxO [9].”
BackgroundTranscriptional mechanisms regulating skeletal muscle differentiation, growth and homeostasis
Braun, T., & Gautel, M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3118 · Cited by 713
FoxO transcription factors in the maintenance of cellular homeostasis during aging
Salih, D. A., & Brunet, A. (2008) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.02.005 · Cited by 604
“Interestingly, the induction of atrogin-1 initiates a positive feedback loop to attenuate cardiac hypertrophy by mediating polyubiquination of FoxO1 and FoxO3 to enhance FoxO transcriptional activity [73].”
BackgroundA review on the mechanisms of blood-flow restriction resistance training-induced muscle hypertrophy
Pearson, S. J., & Hussain, S. R. (2015) · Sports Medicine · doi:10.1007/s40279-014-0264-9 · Cited by 592
“MuRF1 induces muscle atrophy, at least in part, by directly ubiquitinating the thick filament of the sarcomere and causing the proteolysis of myosin proteins [152, 153], whereas MAFbx down-regulates protein synthesis via the ubiquitination of eIF3-f, a protein initiation factor [154].”
BackgroundSignaling pathways controlling skeletal muscle mass
Egerman, M. A., & Glass, D. J. (2014) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2013.857291 · Cited by 555
Self-citationRoles of F-box proteins in cancer
Wang, Z., Liu, P., Inuzuka, H., & Wei, W. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3700 · Cited by 523
Myogenin and Class II HDACs Control Neurogenic Muscle Atrophy by Inducing E3 Ubiquitin Ligases
Moresi, V., Williams, A. H., Meadows, E., Flynn, J. M., Potthoff, M. J., McAnally, J., Shelton, J. M., Backs, J., Klein, W. H., Richardson, J. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.09.004 · Cited by 444
Signaling pathways perturbing muscle mass.
Glass, D. J. (2010) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e32833862df · Cited by 359
Self-citationCardiac Aging: From Molecular Mechanisms to Significance in Human Health and Disease
Dai, D.-F., Chen, T., Johnson, S. C., Szeto, H., & Rabinovitch, P. S. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4179 · Cited by 334
“Suppression of insulin/PI3K signaling activates transcription factor FOXO, which transcribes target genes including atrogin-1, a ubiquitin ligase that promotes calcineurin degradation and prevents NFAT activation (185,186), thereby attenuating cardiac aging, as the calcineurin-NFAT pathway activation is associated wit…”
BackgroundPI3 Kinase Regulation of Skeletal Muscle Hypertrophy and Atrophy
Glass, D. J. (2010) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2010_78 · Cited by 333
Self-citationGenetic association of FOXO1A and FOXO3A with longevity trait in Han Chinese populations
Li, Y., Wang, W.-J., Cao, H., Lu, J., Wu, C., Hu, F.-Y., Guo, J., Zhao, L., Yang, F., Zhang, Y.-X., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp459 · Cited by 323
Duan, J., Gherghe, C., Liu, D., Hamlett, E., Srikantha, L., Rodgers, L., Regan, J. N., Rojas, M., Willis, M., Leask, A., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2011.418 · Cited by 314
Self-citationAtrogin-1 deficiency promotes cardiomyopathy and premature death via impaired autophagy
Zaglia, T., Milan, G., Ruhs, A., Franzoso, M., Bertaggia, E., Pianca, N., Carpi, A., Carullo, P., Pesce, P., Sacerdoti, D., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci66339 · Cited by 147
Hudson, M. B., Woodworth-Hobbs, M. E., Zheng, B., Rahnert, J. A., Blount, M. A., Gooch, J. L., Searles, C. D., & Price, S. R. (2014) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00266.2013 · Cited by 137
“A consequence of increased atrogin-1 expression should be a reduction of Cn protein, because atrogin-1 facilitates the ubiquitination and degradation of Cn in cardiomyocytes (22, 23).”
Cai, X., Zhu, C., Xu, Y., Jing, Y., Yuan, Y., Wang, L., Wang, S., Zhu, X., Gao, P., Zhang, Y., et al. (2016) · Scientific Reports · doi:10.1038/srep26802 · Cited by 54
Retracted
Metadata
- Authors
- Li, H.-H., Willis, M. S., Lockyer, P., Miller, N., McDonough, H., Glass, D. J., & Patterson, C.
- Venue
- Journal of Clinical Investigation
- Published
- 2007-11-01
- Volume
- 117
- Issue
- 11
- Pages
- 3211-3223
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2155581711
- Cited by
- 247
- References
- 2
- FWCI
- 6.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.